Aurora Cannabis Inc. (ACB)
USD 4.24
(-5.15%)
USD 4.24
(-5.15%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 131.46 Million CAD | 304.26% |
| 2022 | -64.35 Million CAD | -403.23% |
| 2021 | 21.22 Million CAD | 198.46% |
| 2020 | -21.55 Million CAD | 35.72% |
| 2019 | -33.53 Million CAD | -120.99% |
| 2018 | 159.81 Million CAD | 267.23% |
| 2017 | 43.51 Million CAD | 171.05% |
| 2016 | 16.05 Million CAD | 2274.2% |
| 2015 | 676.27 Thousand CAD | 321.88% |
| 2014 | -304.79 Thousand CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | -100.0% |
| 2008 | 40.83 Thousand CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q1 | 34.44 Million CAD | 684.72% |
| 2023 Q2 | 19.8 Million CAD | -42.52% |
| 2023 Q3 | 51.16 Million CAD | 158.38% |
| 2023 FY | 131.46 Million CAD | 304.26% |
| 2022 Q3 | 25.03 Million CAD | 254.79% |
| 2022 Q4 | 4.39 Million CAD | -82.46% |
| 2022 Q2 | -16.17 Million CAD | -846.72% |
| 2022 Q1 | -1.7 Million CAD | -138.91% |
| 2022 FY | -64.35 Million CAD | -403.23% |
| 2021 Q4 | 4.39 Million CAD | 130.94% |
| 2021 Q1 | 25.44 Million CAD | 27.67% |
| 2021 FY | 21.22 Million CAD | 198.46% |
| 2021 Q2 | 5.58 Million CAD | -78.07% |
| 2021 Q3 | -14.18 Million CAD | -354.28% |
| 2020 Q4 | 19.93 Million CAD | 123.32% |
| 2020 Q1 | 26.62 Million CAD | 118.41% |
| 2020 Q2 | 17.34 Million CAD | -34.83% |
| 2020 FY | -21.55 Million CAD | 35.72% |
| 2020 Q3 | -85.46 Million CAD | -592.6% |
| 2019 Q3 | 27.4 Million CAD | -8.39% |
| 2019 Q4 | -144.56 Million CAD | -627.52% |
| 2019 Q2 | 29.91 Million CAD | -44.3% |
| 2019 Q1 | 53.7 Million CAD | -19.84% |
| 2019 FY | -33.53 Million CAD | -120.99% |
| 2018 Q4 | 67 Million CAD | 27.33% |
| 2018 FY | 159.81 Million CAD | 267.23% |
| 2018 Q1 | 8.05 Million CAD | -54.49% |
| 2018 Q2 | 32.14 Million CAD | 299.28% |
| 2018 Q3 | 52.62 Million CAD | 63.72% |
| 2017 Q1 | 7.68 Million CAD | 31.49% |
| 2017 Q4 | 17.68 Million CAD | 132.27% |
| 2017 FY | 43.51 Million CAD | 171.05% |
| 2017 Q3 | 7.61 Million CAD | 17.41% |
| 2017 Q2 | 6.48 Million CAD | -15.63% |
| 2016 Q3 | 4.58 Million CAD | 34.62% |
| 2016 Q2 | 3.4 Million CAD | 3851.15% |
| 2016 FY | 16.05 Million CAD | 2274.2% |
| 2016 Q4 | 5.84 Million CAD | 27.43% |
| 2016 Q1 | 86.26 Thousand CAD | 102.05% |
| 2015 FY | 676.27 Thousand CAD | 321.88% |
| 2015 Q4 | -4.2 Million CAD | -12.15% |
| 2015 Q3 | -3.75 Million CAD | -269.06% |
| 2015 Q2 | 2.21 Million CAD | 0.0% |
| 2015 Q1 | - CAD | 100.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q4 | -18.5 Thousand CAD | 0.0% |
| 2014 FY | -304.79 Thousand CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q1 | - CAD | -100.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 FY | - CAD | -100.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2008 Q4 | 40.83 Thousand CAD | 0.0% |
| 2008 FY | 40.83 Thousand CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2007 Q1 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2006 FY | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Theratechnologies Inc. | 62.12 Million USD | -111.592% |
| Harrow Health, Inc. | 90.55 Million USD | -45.175% |
| Dynavax Technologies Corporation | 182.11 Million USD | 27.816% |
| Biofrontera Inc. | 16.62 Million USD | -690.642% |
| Cronos Group Inc. | 6.99 Million USD | -1780.446% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -2670.495% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 70.201% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 43486.139% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -4204.275% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -292.583% |
| Radius Health, Inc. | 307.71 Million USD | 57.278% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -1204.441% |
| DURECT Corporation | 6.83 Million USD | -1824.462% |
| ProPhase Labs, Inc. | 16.23 Million USD | -709.533% |
| Safety Shot Inc | -74.45 Thousand USD | 176658.282% |
| Phibro Animal Health Corporation | 312.48 Million USD | 57.931% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -23630.484% |
| Alvotech | -69.42 Million USD | 289.364% |
| Assertio Holdings, Inc. | 125.04 Million USD | -5.127% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 74.9% |
| Rockwell Medical, Inc. | 8.7 Million USD | -1410.34% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -1476.416% |
| Procaps Group S.A. | 239.56 Million USD | 45.126% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 69.472% |
| SCYNEXIS, Inc. | 124.51 Million USD | -5.576% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -140.831% |
| Viatris Inc. | 6.43 Billion USD | 97.958% |
| OptiNose, Inc. | 62.35 Million USD | -110.828% |
| SIGA Technologies, Inc. | 122.09 Million USD | -7.673% |
| Tilray Brands, Inc. | 223.35 Million USD | 41.142% |
| PetIQ, Inc. | 252.74 Million USD | 47.986% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -1476.416% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 92.884% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -2336.919% |
| Alimera Sciences, Inc. | 61.17 Million USD | -114.909% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 59.696% |
| Silver Spike Investment Corp. | 8.1 Million USD | -1522.442% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 1930213.052% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 57.565% |
| Journey Medical Corporation | 52.52 Million USD | -150.3% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -3036.596% |
| Alpha Teknova, Inc. | 10.29 Million USD | -1176.807% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -1905.186% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -214.122% |
| PainReform Ltd. | -15 Thousand USD | 876500.0% |
| Cosmos Health Inc. | 4.34 Million USD | -2922.368% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -384.788% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -9996.774% |
| Embecta Corp. | 749.9 Million USD | 82.47% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 17731.722% |
| Talphera, Inc. | -4.89 Million USD | 2785.598% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 73.188% |
| Incannex Healthcare Limited | 12 Thousand USD | -1095400.0% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 5554.373% |
| Shineco, Inc. | 882.16 Thousand USD | -14801.923% |
| Procaps Group, S.A. | 239.56 Million USD | 45.126% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 56.941% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -341.853% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 81.473% |
| Alvotech | -69.42 Million USD | 289.364% |
| Hempacco Co., Inc. | -1.21 Million USD | 10912.34% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 40.697% |
| Bright Green Corporation | -237.01 Thousand USD | 55564.61% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -79.917% |
| Kamada Ltd. | 52.59 Million USD | -149.958% |
| Indivior PLC | 907 Million USD | 85.506% |
| Evoke Pharma, Inc. | 4.97 Million USD | -2540.421% |
| Flora Growth Corp. | 17.73 Million USD | -641.121% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 5554.373% |
| Evolus, Inc. | 140.52 Million USD | 6.451% |
| HUTCHMED (China) Limited | 453.55 Million USD | 71.015% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 61.781% |
| Akanda Corp. | 111.44 Thousand USD | -117855.298% |